Navamedic

Navamedic wins joint Nordic antibiotics tender

Oslo, 07 October 2024 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and

reliable provider of high-quality products to hospitals and pharmacies, has

signed joint contracts with Amgros in Denmark, Landspitali Háskólasjúkrahús in

Iceland and Sykehusinnkjøp HF, divisjon legemidler in Norway to be the main

supplier of certain antibiotics to hospital across all three countries. The

contracts start in April 2025 and will run until 2027, with the opportunity for

an extension.

These are the latest of several tenders Navamedic has secured this year,

representing significant growth for the antibiotic's portfolio and predictable

income for the coming years. Together with the recently announced LIS tender,

these represent the largest antibiotics tenders in the Nordics.

"We consider securing this Nordic tender a testament to the quality of our

antibiotic portfolio and our position in the market. Our commitment to

responsible manufacturing of antibiotics has been a cornerstone of our strategy,

and we are proud to see it recognised with this significant tender win," says

Janne Folmoe, Tender Manager at Navamedic ASA.

With new global guidance aimed at reducing antibiotic pollution from

manufacturing, this Nordic tender emphasised the importance of the environment.

Pollution prevention and manufacturing control will play a significant role in

the fight against antimicrobial resistance, and manufacturers and suppliers will

be met with increasingly higher quality criteria. As a member of The AMR

Industry Alliance and with ISO certification, Navamedic has demonstrated that it

is a reliable and responsible supplier of antibiotics.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

Navamedic ASA is a full-service provider of high-quality healthcare products to

hospitals and pharmacies. Navamedic meets the specific medical needs of patients

and consumers by leveraging its highly scalable market access platform, leading

category competence and local knowledge. Navamedic is present in all the Nordic

countries, the Baltics and Benelux, with sales representation in the UK and

Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock

Exchange (ticker: NAVA).

For more information, please visit www.navamedic.com

AI Terminal